Alda gets Australian allowance notice for T36 patent

2007-10-10 10:27 ET - News Release

Dr. Terrance Owen reports

ALDA RECEIVES NOTICE OF ALLOWANCE FOR AUSTRALIAN PATENT

Alda Pharmaceuticals Corp. has been notified that the Australian Patent Office has accepted Alda's patent application that describes the composition and production methods for Alda's T36 formulation.

As in the case of the United States and Chinese patent applications which were also recently approved and reported by the company in news releases in Stockwatch dated June 26 and June 28, 2007, respectively, the Australian patent application covers the process for making the T36 formulation as well as the formulation itself. The components of the T36 formulation act synergistically to disrupt the physical structure of the infectious organisms rather than interfering with their metabolic pathways. This provides a high degree of efficacy and safety, prevents microbial resistance and causes no side effects or toxicity to patients.

Dr. Terrance Owen, president and chief executive officer, states: "Notification that the patent will now be issued in Australia provides further comfort that our intellectual property is very robust. We are gratified to see rapid allowance of the patent applications in a number of jurisdictions. Clearly, ALDA's T36 formulation is unique and is becoming a significant asset to the company."